REASONS FOR DOING THE STUDYFor companies with a focused emerging markets strategy, significant opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from the opportunity.
Therapeutic emerging geographic markets are the fastest growing of all regions across the globe. Market growth has been spurred by the uptake in growth driven by improved socioeconomic conditions, improved patent regimes, and an enhanced healthcare infrastructure.
This study investigates one of the most important market drivers: the increased aging of patients in emerging markets as well as the ability of these patients to pay for, or have paid for, leading healthcare. This dynamic alone is expected to continue to contribute substantially to market growth through the forecast period.
This report analyzes emerging markets by disease segment, company, and brands. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.
SCOPE OF REPORTCurrent and projected product forecasts during the forecast period (2010–2015) are discussed. As well, new products approved in 2009 and 2010 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period, are projected. The figure for 2010 is estimated, except where actual results have been reported, due to the release timing of the report. <
Copyright©2010 PR Newswire.
All rights reserved